Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00052013 |
The purpose of this study is to determine whether PTK787/ZK 222584 is effective in treating hemangioblastoma of the brain and/or retina in patients with von Hippel-Lindau disease. The study will also assess safety and tolerability of PTK787/ZK 222584, and changes in markers of angiogenesis (new blood vessel growth).
Condition | Intervention | Phase |
---|---|---|
Von Hippel-Lindau Disease CNS Hemangioblastoma Retinal Hemangioblastoma |
Drug: PTK787/ZK 222584 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II Open-Label Study of Oral, Continuous, Once Daily PTK787/ZK 222584 in Patients With Von Hippel-Lindau Disease (VHL) and Hemangioblastoma (HB) |
Estimated Enrollment: | 11 |
Study Start Date: | January 2003 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion criteria
Exclusion criteria:
United States, Massachusetts | |
Dana Farber Cancer Institute | |
Boston, Massachusetts, United States, 02115 | |
United States, North Carolina | |
Duke University Medical Center | |
Durham, North Carolina, United States, 27710 |
Study Chair: | Novartis | Novartis |
Study ID Numbers: | CPTK787 0144 |
Study First Received: | January 21, 2003 |
Last Updated: | September 21, 2006 |
ClinicalTrials.gov Identifier: | NCT00052013 |
Health Authority: | United States: Food and Drug Administration |
Angiomatosis Von Hippel-Lindau Disease Hemangioblastoma Hemangioma, Capillary Von Hippel-Lindau syndrome |
Hemangioma Vascular Diseases Vatalanib Neurocutaneous Syndromes |
Neoplasms Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action Nervous System Diseases Neoplasms, Vascular Tissue |
Enzyme Inhibitors Cardiovascular Diseases Protein Kinase Inhibitors Pharmacologic Actions |